NASDAQ:JNCE - Jounce Therapeutics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$4.21 -0.09 (-2.09 %)
(As of 02/15/2019 04:00 PM ET)
Previous Close$4.30
Today's Range$4.19 - $4.48
52-Week Range$2.66 - $29.25
Volume100,300 shs
Average Volume218,516 shs
Market Capitalization$137.67 million
P/E Ratio-7.39
Dividend YieldN/A
Beta3.8
Jounce Therapeutics, Inc., a clinical stage immunotherapy company, develops therapies for the treatment of cancer. Its lead product candidate is JTX-2011, a clinical stage monoclonal antibody that binds to and activates the inducible T cell co-stimulator, a protein on the surface of certain T cells found in solid tumors, which is in Phase I/II clinical trial for the treatment of six tumor types, including head and neck squamous cell cancer, non-small cell lung cancer, triple negative breast cancer, melanoma, gastric cancer, and other tumor types identified through its translational science platform. The company is also developing JTX-4014, an anti-PD-1 antagonist antibody for combination therapy. Jounce Therapeutics, Inc. has a master research and collaboration agreement with Celgene Corporation focused on developing and commercializing biologic immunotherapies. The company was incorporated in 2012 and is headquartered in Cambridge, Massachusetts.

Receive JNCE News and Ratings via Email

Sign-up to receive the latest news and ratings for JNCE and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:JNCE
CUSIPN/A
Phone857-259-3840

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$71.64 million
Book Value$5.18 per share

Profitability

Net Income$-16,440,000.00

Miscellaneous

Employees112
Market Cap$137.67 million
OptionableOptionable

Jounce Therapeutics (NASDAQ:JNCE) Frequently Asked Questions

What is Jounce Therapeutics' stock symbol?

Jounce Therapeutics trades on the NASDAQ under the ticker symbol "JNCE."

How were Jounce Therapeutics' earnings last quarter?

Jounce Therapeutics Inc (NASDAQ:JNCE) posted its earnings results on Friday, August, 10th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.37) by $0.23. The firm earned $19.38 million during the quarter, compared to the consensus estimate of $12.47 million. Jounce Therapeutics had a negative net margin of 59.74% and a negative return on equity of 29.58%. View Jounce Therapeutics' Earnings History.

When is Jounce Therapeutics' next earnings date?

Jounce Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, March 14th 2019. View Earnings Estimates for Jounce Therapeutics.

What price target have analysts set for JNCE?

6 brokerages have issued twelve-month price objectives for Jounce Therapeutics' shares. Their forecasts range from $10.00 to $20.00. On average, they anticipate Jounce Therapeutics' stock price to reach $13.00 in the next year. This suggests a possible upside of 208.8% from the stock's current price. View Analyst Price Targets for Jounce Therapeutics.

What is the consensus analysts' recommendation for Jounce Therapeutics?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Jounce Therapeutics in the last year. There are currently 1 sell rating, 2 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Jounce Therapeutics.

Has Jounce Therapeutics been receiving favorable news coverage?

Media headlines about JNCE stock have trended somewhat positive this week, according to InfoTrie Sentiment. The research firm identifies positive and negative news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Jounce Therapeutics earned a media sentiment score of 1.2 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 2.0 out of 10, indicating that recent news coverage is very unlikely to have an effect on the stock's share price in the next several days.

Who are some of Jounce Therapeutics' key competitors?

Who are Jounce Therapeutics' key executives?

Jounce Therapeutics' management team includes the folowing people:
  • Dr. Richard Murray, Pres, CEO & Director (Age 60)
  • Mr. Hugh M. Cole, Chief Bus. Officer & Head of Corp. Devel. (Age 54)
  • Dr. Elizabeth G. Tréhu, Chief Medical Officer (Age 59)
  • Dr. James P. Allison, Founder
  • Dr. Thomas F. Gajewski, Founder

When did Jounce Therapeutics IPO?

(JNCE) raised $76 million in an initial public offering on Friday, January 27th 2017. The company issued 5,400,000 shares at $13.00-$15.00 per share. J.P. Morgan and Cowen and Company acted as the underwriters for the IPO and Wells Fargo Securities and Baird were co-managers.

Who are Jounce Therapeutics' major shareholders?

Jounce Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include BlackRock Inc. (3.26%), Dimensional Fund Advisors LP (1.40%), Two Sigma Investments LP (1.23%), Two Sigma Advisers LP (0.82%), Millennium Management LLC (0.67%) and Connor Clark & Lunn Investment Management Ltd. (0.51%). Company insiders that own Jounce Therapeutics stock include Barbara Gayle Duncan, Elizabeth Trehu, Hugh M Cole, Kimberlee C Drapkin and Richard /Ca/ Murray. View Institutional Ownership Trends for Jounce Therapeutics.

Which major investors are selling Jounce Therapeutics stock?

JNCE stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, BlackRock Inc. and Barclays PLC. Company insiders that have sold Jounce Therapeutics company stock in the last year include Barbara Gayle Duncan, Elizabeth Trehu, Kimberlee C Drapkin and Richard /Ca/ Murray. View Insider Buying and Selling for Jounce Therapeutics.

Which major investors are buying Jounce Therapeutics stock?

JNCE stock was purchased by a variety of institutional investors in the last quarter, including Two Sigma Investments LP, Acadian Asset Management LLC, Two Sigma Advisers LP, Squarepoint Ops LLC, Alambic Investment Management L.P., Assenagon Asset Management S.A., Connor Clark & Lunn Investment Management Ltd. and Creative Planning. View Insider Buying and Selling for Jounce Therapeutics.

How do I buy shares of Jounce Therapeutics?

Shares of JNCE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Jounce Therapeutics' stock price today?

One share of JNCE stock can currently be purchased for approximately $4.21.

How big of a company is Jounce Therapeutics?

Jounce Therapeutics has a market capitalization of $137.67 million and generates $71.64 million in revenue each year. The company earns $-16,440,000.00 in net income (profit) each year or ($0.57) on an earnings per share basis. Jounce Therapeutics employs 112 workers across the globe.

What is Jounce Therapeutics' official website?

The official website for Jounce Therapeutics is http://www.jouncetx.com.

How can I contact Jounce Therapeutics?

Jounce Therapeutics' mailing address is 780 MEMORIAL DRIVE, CAMBRIDGE MA, 02139. The company can be reached via phone at 857-259-3840.


MarketBeat Community Rating for Jounce Therapeutics (NASDAQ JNCE)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  179 (Vote Outperform)
Underperform Votes:  153 (Vote Underperform)
Total Votes:  332
MarketBeat's community ratings are surveys of what our community members think about Jounce Therapeutics and other stocks. Vote "Outperform" if you believe JNCE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe JNCE will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/16/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel